Page results
-
Research conducted at UCLH has discovered how some skin cancers stop responding to treatment at the end of life.
-
Information for outpatients visiting UCLH hospitals.
-
"Patient-initiated follow-up” appointments (PIFU ) allow you to arrange a follow-up appointment if and when you need it.
-
Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes.
-
Prime Minister Boris Johnson came to the UCLH vaccination centre based at The Francis Crick Institute to receive his second COVID-19 vaccination.
-
The Patient Advice and Liaison Service (PALS) provides impartial advice and assistance in answering questions and resolving concerns that patients, their relatives, friends and carers might have accessing the NHS services provided by UCLH.
-
Thrombotic Thrombocytopenia Purpura (TTP) is a rare disorder of the blood coagulation system.
-
UCLH Charity’s magazine, Charity Matters is out now.
-
The Government has now set out further action aimed at tackling rising cases of the COVID-19 B1.617.2 variant of COVID-19 (also known as the Indian variant).
-
We are excited to share news that Genomics England has launched an initiative that will directly benefit patients from underrepresented populations such as those living with sickle cell disorder.
File results
-
FOI/2023/0007 - Outpatient activity for 2022
-
FOI/2023/0009 - Procedure volumes/ average costs for portable and stable oxygen concentrator devices
-
FOI/2023/0010 - Bardet-biedle Syndrome patient treatment and diagnosis
-
FOI/2023/0013 - Average waiting times for colonoscopy investigations
-
FOI/2023/0014 - Surgery protocols/ standard operating procedures for a feticide
-
FOI/2023/0018 - A&E attendances/ admissions by patients of no fixed abode
-
FOI/2023/0019 - Public access to water refill stations on your premises
-
FOI/2023/0022 - Guidelines staff follow for patients with disabilities and autism
-
FOI/2023/0226 - Treatment with Nivolumab
-
FOI/2023/0225 - Usage of Dabrafenib + Trametinib in cancer treatment